secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250709
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M
--------------------------------------------------------------------------------

- Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.
- Gross proceeds of approximately $23.0 million; net proceeds for working capital and clinical development.
- Directors and officers subject to lock-up restricting share sales until January 22, 2026.
- Financial advisor to receive 100,000 warrants at $5.50 exercise price and $200,000 fee.
- Lucid Capital Markets is sole book-runner; Allele Capital Partners acted as financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/0001193125-25-250709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/d52085d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer